CANBERA (dpa-AFX) - CSL Ltd. (CSL.AX) Friday said Health Canada has approved Andembry for the treatment of hereditary angioedema (HAE) in patients aged 12 years and older.
HAE is a genetic disorder characterized by recurrent and unpredictable attacks of angioedema.
Health Canada authorization is based on data from the Phase 3 VANGUARD study, in which Andembry reduced HAE attacks by a median of more than 99 percent compared to placebo.
Andembry is already approved in several countries, including the U.S, Australia, the United Kingdom, the European Union, Switzerland, and Japan.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
